Copyright
©The Author(s) 2025.
World J Diabetes. Jun 15, 2025; 16(6): 105711
Published online Jun 15, 2025. doi: 10.4239/wjd.v16.i6.105711
Published online Jun 15, 2025. doi: 10.4239/wjd.v16.i6.105711
Table 2 Role of extracellular vesicles derived from stem cells on apoptosis in a high glucose cell models and animal models of diabetic kidney disease
Exosome source | Animal models | miRNA | Dose | Injection method | Frequency/time | Outcomes | Ref. |
BM-MSCs | Renal tubular epithelial cells | 5.3 × 107 | Co-culture | 96 hours | ↓TGF-β 1, ↓Apotpsis, ↑ZO-1 | [92] | |
BM-MSCs | HUVECs | miR-146a-5p | 100 μL | Co-ulture | 48 hours | ↑IL-10, ↓apoptosis rate, NF-KB | [93] |
AD-MSCs | MPC5 | miR-486 | 25 μg/mL | Co-culture | 48 hours | Cleaved caspase-3↓ | [94] |
AD-MSCs | db/db | miR-486 | Tail vein | 12 weeks | ↓Cleaved caspase-3, ↓p-mTOR | [94] | |
AD-MSCs | MPC 5 | miR-15b-15p | 25 μg/mL | Co-culture | 24 hours | ↑Caspase3, Bcl2, ↓cleaved caspase3 | [96] |
AD-MSCs | SD rats with type 1 diabetes | MiR-125a | 50 μg | Tail vein | Twice a week for 3 weeks | ↓Bax, ↑Bcl2, ET1↓ | [97] |
AD-MSCs | MP5 cells | miR-26a-5p | 25 mg/mL | Co-culture | 48 hours | ↓Cleaved caspase-3, Bax↓ Bcl2↑ | [98] |
AD-MSCs | db/db mice | miR-26a-5p | Tail vein | Once at 13 weeks | ↓TUNEL + cells; ↓cleaved caspase-3, Bax; ↑Bcl2 | [98] | |
HUC-MSCs | Podocytes | 30 μg/mL | Co-culture | 48 hours | ↑Podocytes cell viability, ↓apoptosis of podocytes | [99] | |
HUC-MSCs | HK2 cells | miR-424-5p | 50 μg/mL | Co-culture | 48 hours | ↓Apoptosis rate, ↓TUNEL + cells, ↓Bax,cleaved caspase-3/caspase-3, ↑Bcl2 | [100] |
HUC-MSCs | db/db | miR-424-5p | 10 mg/kg bw | Tail vein | twice a week for 6 weeks | ↓Bax, cleaved caspase-3/total caspase-3, ↑Bcl2 | [100] |
HUC-MSCs | STZ-induced SD rat | Mi-R-146a-5p | 2 × 106 | Tail vein | Once a week for 2 weeks | ↑IL-10, M2 macrophage marker; ↓IL-1β, IL-6 and TNF-αmRNA, TRAF6, M1 macrophage marker | [101] |
HUC-MSCs | Type 2 diabetic BKS. db/db mice | MiR-22-3p | Exo 20, μg/mL | Tail Vein | 3 times in the first week, twice a week in the next 3 weeks | ↑wnt-1; ↓ Caspase-1, ASC | [102] |
HUC-MSCs | Podocytes | MiR-22-3p | 20 μg/mL | Co-culture | 24 hours | ↑Podocytes cell viability; ↓apoptosis of podocytes; ↓Caspase-1 | [102] |
USCs | STZ-induced SD rat | VEGF, TGF-β1, angiogenin, BMP-7 | 100 μg | Tail vein | Weekly for 12 weeks | ↓Apoptosis rate; ↓TUNEL + cells; ↓caspase-3 | [103] |
USCs | HPDCs | miR-16-5p | 0.4 × 105 cells | Co-culture | 4-5 days | ↑Podocyte viability; ↓apoptosis rate, Bax, Caspase-3, α-SMA, VEGFA | [104] |
USCs | STZ induced SD rat | miR-16-5p | 100 μg | Tail vein | once a week for 12 weeks | ↓VEGFA, MCP-1, TGF-β1, TNF-α | [104] |
USCs | STZ-induced SD rat | 2 × 106 cells | Tail vein | Six times every other week | ↓TUNEL + cells; ↓caspase-3 | [105] |
- Citation: Nie P, Qin W, Nie WC, Li B. Progress in the application of mesenchymal stem cells to attenuate apoptosis in diabetic kidney disease. World J Diabetes 2025; 16(6): 105711
- URL: https://www.wjgnet.com/1948-9358/full/v16/i6/105711.htm
- DOI: https://dx.doi.org/10.4239/wjd.v16.i6.105711